Bayer Faces Dual Legal and Analyst Crosscurrents as Brazilian Glyphosate Ban Bid Spooks Investors

A Brazilian civil lawsuit seeking a glyphosate ban adds legal risk for Bayer, outweighing a Jefferies price-target hike. Stock falls 3.57% as herbicide sales already decline.

Bayer enters the trading week with its legal calendar expanding on a new continent, just as an analyst upgrade underscores how deeply the stock’s valuation remains tethered to courtroom outcomes. A Brazilian civil lawsuit seeking a blanket prohibition of glyphosate has injected fresh uncertainty into the agrochemical giant’s most important herbicide market, outweighing a modest price-target increase from Jefferies.

The stock closed at €36.48 on Friday, shedding 3.57% on the day and leaving it with a weekly loss of 4.98%. The selloff snapped a longer recovery trend that had carried the shares 47.78% higher over the past 12 months, though they now trade 25.81% below their 52-week high and 5.80% beneath their short-term moving average.

Brazil Takes Aim at the Heart of Crop Science

The trigger for the decline was a civil action filed on May 22 by Brazil’s Ministério Público do Trabalho against the health regulator Anvisa and the federal government. The complaint seeks to cancel all registrations for glyphosate-based products across production, import, export, marketing and use, citing worker-safety risks. An independent agricultural source described the case as newly opened, with no final court ruling on the horizon — a vacuum that leaves the market guessing about the potential scale of disruption.

Brazil is one of the world’s largest pesticide markets and glyphosate is the most widely used herbicide there. A ban would directly hit Bayer’s Crop Science division, which reported a 6.8% currency- and portfolio-adjusted revenue rise to €7.558 billion in the latest quarter. Earnings before interest, tax, depreciation and amortisation before special items jumped 17.9% to €3.014 billion, with a margin of 39.9%. Yet within that strong performance, herbicide sales slid 10.2%, and glyphosate-containing products dropped 15.1%. The Brazilian challenge thus lands on a business line already contracting.

Bayer repeated its longstanding safety position, pointing to repeated regulatory assessments worldwide that have found glyphosate can be used safely and is not carcinogenic. Anvisa itself upheld glyphosate’s registration under restricted conditions in 2020. The new lawsuit, however, pushes for a far wider prohibition, escalating the regulatory conflict.

Jefferies Sees Value but Not a Clear Buy

Against this backdrop, Jefferies lifted its price target for Bayer from €25 to €40, while keeping a “Hold” rating. New pharma analyst Michael Leuchten based his valuation on a sum-of-the-parts model that yields €45 per share. Yet he also outlined a negative scenario in which persistent legal risks drag the stock to €30. That €15 range captures the fundamental tension: Bayer looks cheap on the surface, but the discount reflects unresolved litigation.

Beyond glyphosate, the company faces fresh allegations in the US over an alleged seed monopoly, adding another layer of cost uncertainty. In the February 2026 quarter, Bayer reached two significant settlement agreements on Roundup claims without admitting liability or wrongdoing, but the volume of new cases continues to flow. The capital market keeps demanding a risk premium accordingly.

Dividend Stays Minimal as Next Catalyst Looms

For the 2025 financial year, Bayer paid a dividend of €0.11 per share, approved at the annual general meeting on April 24. The payout, the legal minimum, signals that the company is conserving cash while navigating legal and operational headwinds. Earnings per share for 2026 are estimated at €4.35.

Technically, the stock sits below its 50-day moving average of €38.73 but above the 200-day line of €35.63, suggesting a bruised sideways drift rather than a clear directional break.

The next scheduled financial report is the half-year results on August 4. Until then, the trajectory of the Brazilian case — whether it moves quickly toward a concrete restriction or remains an opening legal gambit — will likely dictate short-term sentiment. With Crop Science still delivering solid operating numbers, investors are left weighing the strength of the underlying business against a legal overhang that, geographically at least, keeps getting wider.